News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)’s BRILINTA® (ticagrelor) Added to American College of Chest Physicians Recommendations on Antithrombotic Therapy and Prevention of Thrombosis



2/21/2012 8:16:53 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) announced today that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA® (ticagrelor) tablets with low-dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES